Merck announced on September 11, 2025, that its pneumonia shot, Capvaxive, showed strong immune responses in children and teens who are at higher risk of serious illness. These results were based on a late-stage study presented at a vaccines meeting in Lisbon.
The positive data indicates the potential to expand the use of Capvaxive to a younger, vulnerable population. This development reinforces the vaccine's broad utility and Merck's commitment to pneumococcal disease prevention across different age groups.
This successful late-stage trial strengthens Merck's vaccine pipeline and its position in the infectious disease market. It provides further evidence for Capvaxive's efficacy and safety profile, supporting future regulatory submissions for this demographic.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.